Barclays lowered the firm’s price target on Elevance Health (ELV) to $385 from $395 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q3 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Reports Strong Q3 2025 Revenue Growth
- Morning Movers: General Motors and RTX higher following Q3 reports
- Elevance Health reports Q3 adjusted EPS $6.03, consensus $4.94
- Elevance Health backs FY25 adjusted EPS view of ~$30.00, consensus $29.89
- Elevance Health backs FY25 benefit expense ratio ~90%